MX373700B - Composicion acuosa novedosa. - Google Patents

Composicion acuosa novedosa.

Info

Publication number
MX373700B
MX373700B MX2017007573A MX2017007573A MX373700B MX 373700 B MX373700 B MX 373700B MX 2017007573 A MX2017007573 A MX 2017007573A MX 2017007573 A MX2017007573 A MX 2017007573A MX 373700 B MX373700 B MX 373700B
Authority
MX
Mexico
Prior art keywords
aqueous composition
novel aqueous
salt
brimonidine
solvate
Prior art date
Application number
MX2017007573A
Other languages
English (en)
Other versions
MX2017007573A (es
Inventor
Isamu Sawai
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2017007573A publication Critical patent/MX2017007573A/es
Publication of MX373700B publication Critical patent/MX373700B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporciona una técnica para suprimir la precipitación de cristales de una composición acuosa que contiene un derivado de isoquinolina halogenado durante la conservación a baja temperatura; una composición acuosa que comprende un compuesto representado por la fórmula (1): (ver Fórmula) en donde x representa un átomo de halógeno, o una sal del mismo, o un solvato del compuesto o la sal del mismo, y brimonidina o una sal de la misma.
MX2017007573A 2014-12-12 2015-12-11 Composicion acuosa novedosa. MX373700B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014251708 2014-12-12
PCT/JP2015/084802 WO2016093344A1 (ja) 2014-12-12 2015-12-11 新規水性組成物

Publications (2)

Publication Number Publication Date
MX2017007573A MX2017007573A (es) 2018-01-17
MX373700B true MX373700B (es) 2020-05-07

Family

ID=56107521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007573A MX373700B (es) 2014-12-12 2015-12-11 Composicion acuosa novedosa.

Country Status (11)

Country Link
US (1) US10220043B2 (es)
EP (1) EP3231429B1 (es)
JP (2) JP5951920B1 (es)
KR (1) KR102502053B1 (es)
CN (1) CN107106571B (es)
BR (1) BR112017012487A2 (es)
CA (1) CA2970263A1 (es)
MX (1) MX373700B (es)
MY (1) MY178881A (es)
SG (1) SG11201704737SA (es)
WO (1) WO2016093344A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178371A (en) * 2014-09-25 2020-10-09 Kowa Co Pharmaceutical preparation
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
US20210106569A1 (en) * 2017-12-21 2021-04-15 Santen Pharmaceutical Co., Ltd. Omidenepag combination
JP6628924B2 (ja) * 2018-06-05 2020-01-15 千寿製薬株式会社 水性液剤
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
CN109734701B (zh) * 2019-03-04 2020-07-14 中国药科大学 Rock抑制剂-二氯乙酸复盐及其制备方法和用途
CN111518028B (zh) * 2020-05-12 2024-06-25 中国药科大学 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
CN116159018B (zh) * 2023-03-01 2024-11-01 中国药科大学 一种新型外用溴莫尼定凝胶剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
KR101194123B1 (ko) * 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
EP1902731B1 (en) * 2005-06-21 2013-04-10 Kowa Company, Ltd. Preventive or remedy for glaucoma
JP4800720B2 (ja) 2005-09-21 2011-10-26 興和株式会社 点眼用組成物
JP2012250953A (ja) * 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とα２受容体作動薬の組合せ剤
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
TWI699205B (zh) 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法

Also Published As

Publication number Publication date
US20170360799A1 (en) 2017-12-21
EP3231429B1 (en) 2021-03-17
US10220043B2 (en) 2019-03-05
JPWO2016093344A1 (ja) 2017-04-27
SG11201704737SA (en) 2017-07-28
MX2017007573A (es) 2018-01-17
JP2016155870A (ja) 2016-09-01
CN107106571A (zh) 2017-08-29
BR112017012487A2 (pt) 2017-12-26
KR20170095847A (ko) 2017-08-23
EP3231429A4 (en) 2018-08-08
CN107106571B (zh) 2021-02-05
WO2016093344A1 (ja) 2016-06-16
JP5951920B1 (ja) 2016-07-13
CA2970263A1 (en) 2016-06-16
EP3231429A1 (en) 2017-10-18
KR102502053B1 (ko) 2023-02-20
MY178881A (en) 2020-10-21

Similar Documents

Publication Publication Date Title
MX373700B (es) Composicion acuosa novedosa.
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
PH12016500169A1 (en) Polymorph of syk inhibitors
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX387483B (es) Preparación farmacéutica.
MX389304B (es) Producto farmaceutico.
WO2016011390A8 (en) Irak4 inhibiting agents
MX2017001980A (es) Derivado de quinolina muy puro y metodo para su produccion.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX374439B (es) Compuesto de piridona como inhibidor de c-met
MX2017007574A (es) Composicion.
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
MX2015017156A (es) Inhibidores de bace.
MX2017007572A (es) Composicion acuosa.
MX387796B (es) Compuestos de aminocarbonilcarbamato.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MY177032A (en) Aqueous composition
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
UA93929U (uk) Спосіб одержання 1-метил-3-арил-1,2-дигідро-2-хінолонів
UA98157U (uk) Метиламонієва сіль 2-(4-аміно-5-(4-третбутилфеніл)-4н-1,2,4-триазол-3-ілтіо)ацетатної кислоти, що проявляє протимікробну активність
MY199524A (en) Anti-angiogenic agents and uses thereof
MY181470A (en) Novel fluorinated benzilic acid ester compound and salt thereof

Legal Events

Date Code Title Description
FG Grant or registration